No Data
No Data
Apellis Pharmaceuticals Analyst Ratings
Scotiabank Initiates Apellis Pharmaceuticals at Sector Perform With $35 Price Target
Express News | Apellis Pharmaceuticals Inc : William Blair Initiates Coverage With Outperform Rating; Fair Value Estimate $50
Express News | Apellis Announces Oral Presentation at American Society of Nephrology (Asn) Kidney Week on Phase 3 Valiant Study of Pegcetacoplan in C3G and Primary Ic-Mpgn
Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
Wolfe's Tax Loss Selling Stocks Within Communications, Discretionary, Staples, Energy, Financials, Health Care